KNOWLEDGE BANK

Interviews

From Listening to Leading: Reimagining HEOR Through the Lens of Patient-Centred Evidence

Co-Founder & Director, MarksMan Healthcare
Dimple Dang CoFounder of MarksMan Healthcare is a strategic growth architect shaping the firms global footprint She forges highimpact collaborations leads business expansion and builds a talent ecosystem aligned with excellence Her leadership elevates credibility strengthens brand equity and positions MarksMan as a trusted strategic partner delivering value across global healthcare markets

Articles

Impact Assessment of US Tariff Threat on Indian Healthcare Export

The ongoing tariff fusillades and retorts by the economies like China have precipitated several conundrums and made the trade future nebulous The flat per cent of reciprocal tariff across the sectors include the medical device also The pharmaceutical sector has been kept exempted The current tariff of the Indian drug to the US is zero while the tariffs on US medicines by India is per cent per c...

Research Insights

Regulatory Approval Of Pharmaceuticals Without A Randomised Controlled Study: Analysis Of Ema And Fda Approvals 1999–2014

Abstract Introduction The efficacy of pharmaceuticals is most often demonstrated by randomised controlled trials RCTs however in some cases regulatory applications lack RCT evidence Objective To investigate the number and type of these approvals over the pa

Case Studies

Variation In Adverse Drug Reactions Listed In Product Information For Antidepressants And Anticonvulsants, Between The Usa And Europe: A Comparison Review Of Paired Regulatory Documents

Abstract Objective To compare consistency of adverse drug reaction ADR data in publicly available product information documents for brand drugs between the USA and Europe and to assess the usefulness of information for prescribers and patients Design A comparison review of product info

Techno Trends

Biogen Develops QALSODY®, the First Therapy to Treat a Rare, Genetic Form of ALS

Biogen has developed QALSODY a groundbreaking therapy for adults with amyotrophic lateral sclerosis linked to a mutation in the superoxide dismutase gene

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

Reshaping the Clinical Trial Model

Anna Hayes

Anna Hayes is a senior data management leader (At Veramed) with nearly 20 years of experience in clinical research. She specializes in biometrics strategy, innovation, and operational excellence, driving smarter oversight and data-driven trial execution. Anna is passionate about integrating people, processes, and technology to future-proof clinical trials and elevate data quality.

2

Machine Learning for New Drugs

Sneha Rai

Sneha Rai completed her Ph.D. from Computational and Structural Biology Lab., Department of Biological Sciences and Engineering at Netaji Subhas Institute of Technology (DU). She did masters in Bioinformatics from Banaras Hindu University and holds six years of bioinformatics research experience. Her area of interest includes structural bioinformatics, systems biology, protein/gene network analysis, data mining, computer aided drug designing, computational genomics, NGS data analysis, variant analysis and their clinical interpretation.

 

Venugopal Bhatia

Venugopal Bhatia graduated from NSIT in 2019 with a B.E. in Biotechnology. During his undergraduate studies he was involved as an undergraduate researcher at the Computational and Structural Biology Laboratory and worked on two projects which were later published in Nature Scientific Reports and Elsevier Computational Biology and Chemistry. After a brief stint in industry, he's now pursuing his Master's at Yale.

 

Sonika Bhatnagar

Sonika Bhatnagar, Ph.D. (Biophysics), AIIMS works in the broad area of computational molecular biology. Her laboratory uses techniques of drug target selection, drug design & discovery, machine learning, and integrative genomics & proteomics towards Cardiovascular disease drug design and infectious disease therapeutics.

 

3

Analysis of Blood Microbiota Compositionin Cardiovascular Disease Patients

Ikram Khan

Dr. Ikram Khan, the first author of the Article, Studying Medical Microbiology in Lanzhou University China as a PhD student, and working on blood microbial Ecology and their association with cardiovascular disease. In March 2022, we published two Articles on this work. Email: ikram2018@lzu.edu.cn

 

Imran Khan

Assistant Professor Imran Khan, 2nd Author of this article, Supervises BS(Hons) students and is engaged in the teaching and research of Bacteriology, Nano-medicine, and Molecular Biology. Presently working as, a member of Quality Enhancement Cell at Xcito School of Nursing and Allied Health Sciences Pakistan. Email:Imran.mic727@gmail.com

 

Zhou Jianye

Professor Zhou Jianye, is also Co-supervisor of this study, and supervises Master students. He Engaged in the Teaching and Research of Stomatology and Microbial Ecology at School of Northwest Minzu University”.Email: 14092785@qq.com

 

Xie Ping

Professor Xie Ping, supervises Master and PhD students.She has long been engaged in the research of cardiovascular disease pathogenesis and drug prevention. Her current status is “Director of Cardiovascular Center of Gansu Provincial Hospital”.

 

Li Zhiqiang

Professor Li Zhiqiang, is a Co-supervisor of this study, and supervises Master and PhD students. He Engaged in the Teaching and Research of Stomatology and Microbial Ecology. His current status is “Director of graduate School of Northwest Minzu University”. Email: Lizhiqiang6767@163.com

 

An Lizhe

Professor An Lizhe, supervise this work as a First Supervisor. He supervises PhD and doctoral students, and engaged in the Teaching and Research of Molecular Biology, Environmental Botany and Ecology. Currently working as, a President and Deputy Secretary of the Party Committee of Beijing Forestry University. Email: yxlzq@xbmu.edu.cn

 

Zhang Xiaowei

Dr. Zhang Xiaowei is a professor, chief physician, director of the second ward of cardiovascular medicine, and deputy director of the Science and Technology Department. He has completed projects such as epidemiological investigation and prevention plan research of hypertension in Gansu Province and has published many SCI and CSCD papers, and currently undertakes 1st national natural science foundation, 2nd provincial natural science foundations, and 1st municipal science foundation.

 

4

Precision medicine for Alzheimer’s Disease

Dr. Parmi Tripathi

Dr Parmi is a scientific researcher and an expert medical writer with Ph.D specialising in neurosciences. With an extensive pharmaceutical and healthcare industry experience, she excels at driving innovation. Focused at patient’s centricity, she has played key role in developing innovative medicines that makes meaningful impact on patient’s lives. Dr Parmi has made significant contribution at establishing a patented mouth-dissolving strip (MDS) manufacturing facility. With proven expertise in novel product development, her strong emphasis on quality manufacturing has led to structuring of quality documentation practices for this novel & patented MDS technology aligned with regulatory standards.

Dr Parmi has made significant contributions in field of neuroscience research with multiple acclaimed publications. A distinguished medical writer, she serves as editorial board member and peer reviewer in prestigious journals and continuous to make an impact in her field. Author at reputed public health platform, she writes to promote health awareness. Recognised for her exceptional contributions, she is a multiple-time government R&D grant recipient, particularly in neurodegenerative disorder studies.

5

Single Domain Antibody

Marco Pirisinu

Dr. Marco Pirisinu graduated from the University of Sassari, Italy, with a degree in Biomedical Sciences focusing on the novel design and application of cell penetrating peptide targeting mitochondria. He has more than 10 years of research experience working with academic institutions and biotechnology companies. His primary research interest are nanomedicine, targeted therapy and drug delivery systems. Dr. Pirisinu is first author and corresponding author of peer reviewed articles and Guest Editor forSCI-indexed journals. He is currently Senior Scientist at City University of Hong Kong and Head of Innovative Product Development at Jotbody (HK) Limited.

 

Likun Wei

Dr. Likun Wei obtained his BEng from Tianjin University of Technology, majoring in computer science and MSA from Shanghai Ocean University, majoring in agriculture.He completed his PhD in Biomedical Sciences at City University of Hong Kong in 2021. His PhD work demonstrated a small shark model for affordable high affinity sdAb production.He has co-authored 12 publications in SCI-indexed journals including Nature Communications, Bioresource Technology, Journal of Extracellular Vesicles, Iscience, The Journal of Immunology, and Frontiers in Bioengineering and Biotechnology.  Dr. Likun Wei is currently R&D Lead at Jotbody (HK) Limited.

 

press releasesRead more...

Merck Opens €300 Million Asia-Pacific Bioprocessing Center in Daejeon, South Korea

Merck a leading science and technology company today opened its new AsiaPacific Bioprocessing Production Center in Daejeon South Korea The center represents an investment of more than million the companys largest Life Science investment in AsiaPacific to date

Flagship Pioneering Forms Etcelera to Move Drug Discovery from Probability to Prediction

Flagship Pioneering a scientific innovation engine for transformative platforms and products today announced the formation of Etcelera a company created by the merger of the platforms of Cellarity Cellarity Platform Inc Etiome and Empress Therapeutics to pioneer causal intelligence in human biology...

Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma

Shanghai Junshi Biosciences Co Ltd a leading innovationdriven biopharmaceutical company dedicated to the discovery development and commercialization of novel therapies announced that the supplemental new drug application for the companys product toripalimab injection subcutaneous injection

HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia

HUTCHMED China Limited today announces that the US Food and Drug Administration FDA has granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia ITP an autoimmune disorder that can lead to increased

Transpharmation Ltd. Announces Strategic Acquisition of OrganoTherapeutics SARL

Were delighted to announce the strategic acquisition of OrganoTherapeutics SARL a leader in patientderived organoid technologies that advance the discovery and development of novel therapies for neurodegenerativeCNS disorders

EVERSANA Expands Global Commercialization and AI-Powered HEOR Capabilities with Acquisition of U.K.-based Estima Scientific

EVERSANA a global provider of modern AIpowered commercial services for the biopharmaceutical industry today announced the acquisition of Estima Scientific an innovative Londonbased health economics and outcomes research HEOR technology and services company

EventsRead more...

02 - 04

Nov 2026

Pharma Forum EMEA 2026

Dom Pedro Lisboa Hotel, Lisbon...

02 - 04

Nov 2026

Cancer R&D 2026

Houston, TX, USA

03 - 05

Nov 2026

10th Dermatology Drug Development

Boston, Massachusetts at The C...

03 - 04

Nov 2026

PDA Aseptic Processing of Biopharma Conference

Sheraton Grand Incheon Hotel,...

04 - 05

Nov 2026

Advanced Therapies USA

Hynes Convention Center, Bosto...

05 - 05

Nov 2026

PDA Contamination Control Strategy Workshop

Sheraton Grand Incheon Hotel,...

09 - 11

Nov 2026

11th Microbiome Movement USA Summit

The Colonnade Hotel, Boston, M...

10 - 11

Nov 2026

Extractables & Leachables Europe

Parkhotel Schӧnbrunn, Vienna,...

LATEST NEWSRead more...

Edison Scientific Enters into Agreement with Pfizer to Advance Drug Research and Development

Edison Scientific has entered into an agreement with Pfizer to introduce its Edison AI Platform and AI scientist Kosmos across Pfizers biopharmaceutical research and development activities The collaboration will combine Edison Scientifics artificial intelligence AI technology with Pfizers scientific...

Appian and PSI CRO Partner to Advance AI-driven Clinical Trial Operations

Appian and PSI CRO have entered into a strategic partnership to introduce an artificial intelligence AIpowered solution for clinical trial site identification and selection The solution is now live and is designed to automate site selection across different therapeutic areas medical conditions and...

Adalvo Acquires Romiplostim Biosimilar from Enzene

Adalvo has acquired a romiplostim biosimilar programme from Enzene expanding its portfolio of biosimilars and strengthening its presence in complex biological medicines The programme references Nplate romiplostim a medicine used to treat immune thrombocytopenia ITP in adults and children with chroni...

Twist Bioscience Launches Express Screening Antibodies for Faster Characterisation

Twist Bioscience has expanded its antibody production and characterisation portfolio with the launch of Twist Express Screening Antibodies a service designed to help researchers evaluate large numbers of antibody candidates more quickly The service uses a highthroughput cellfree production process t...

Astellas Enters into Agreement with Audax for Immuno-Oncology Candidate DAX-044

Astellas Pharma and Audax Biosciences have entered into an exclusive option and licence agreement for DAX an investigational antibodycytokine fusion being developed for cancer immunotherapy DAX is designed to deliver interleukin IL an immuneactivating protein more selectively to the tumour microenvi...

Sumitomo Pharma’s Enzomenib Receives Breakthrough Therapy Designation for Relapsed or Refractory KMT2A-Rearranged Acute Leukaemia

Sumitomo Pharma America has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to enzomenib DSP for treating patients with relapsed or refractory acute leukaemia carrying a KMTA gene rearrangement